FindTrial
Sign In

Impact of CINV on Muscle Depletion during Cisplatin based treatment

Impact of CINV on Muscle Depletion during Cisplatin based treatment - Impact of CINV on Muscle Depletion during Cisplatin based treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000036383
Enrollment
30
Registered
2019-04-02
Start date
2018-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic Malignancy

Interventions

None listed

Sponsors

Shizuoka Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Eligible patients are 20 years old or older, Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, histologically or cytologically confirmed thoracic malignant disease, and scheduled to receive first-course cisplatin (60 mg/m2 and more) combination therapy.

Exclusion criteria

Exclusion criteria: Lack of CT scan three months later from the start of treatment

Design outcomes

Primary

MeasureTime frame
changes of skeletal muscle mass in three months from the start of treatment—

Secondary

MeasureTime frame
we explored clinicopathologic factors other than CINV or CIA associated with decrease of skeletal muscle mass.—

Countries

Japan

Contacts

Public ContactEriko Miyawaki

Shizuoka Cancer Center Division of Thoracic Oncology

e.miyawaki@scchr.jp055-989-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026